1

1 Estimates of Actual and Potential Lives Saved in the United States from the use of 2 COVID-19 Convalescent Plasma

- 3 Quigly Dragotakes¹, Patrick W. Johnson², Matthew R. Buras³, Rickey E. Carter⁴, Michael J.
- 4 Joyner⁵, Evan Bloch⁶, Kelly A. Gebo⁷, Daniel F. Hanley⁸, Jeffrey P. Henderson⁹, Liise-anne
- 5 Pirofski¹⁰, Shmuel Shoham⁷, Jonathon W. Senefeld¹¹, Aaron AR Tobian⁶, Chad C. Wiggins¹², R.
- 6 Scott Wright¹³, Nigel S. Paneth¹⁴, David J. Sullivan¹, Arturo Casadevall¹
- 7 ¹Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public
- 8 Health, Baltimore, MD
- ² Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL, USA.
- ³ Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA
- ⁴Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA
- ⁵Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN
- ⁶Department of Pathology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore,
- 14 Maryland, USA
- ⁷Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Johns
- 16 Hopkins University, Baltimore, Maryland, USA
- ⁸Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins School of Medicine, Johns
- 18 Hopkins University, Baltimore, Maryland, USA
- ⁹Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine,
- 20 Louis, St. Louis, MO
- 21 ¹⁰Division of Infectious Diseases, Albert Einstein College of Medicine, New York, NY
- ¹¹Department of Health and Kinesiology, University of Illinois Urbana-Champaign, Urbana, IL
- 23 ¹²Department of Kinesiology, Michigan State University, East Lansing, MI
- ¹³Departments of Cardiovascular Medicine and Human Research Protection Program, Mayo
- 25 Clinic, Rochester, MN, USA
- 26 ¹⁴Department of Epidemiology and Biostatistics and Department of Pediatrics and Human Development,
- 27 Michigan State University, East Lansing, MI
- 28

30 Abstract

- 31 In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent
- 32 plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP
- 33 during the first year of the pandemic. In this study, estimated the number of actual inpatient lives
- 34 saved by CCP treatment in the USA based upon CCP weekly use, weekly national mortality
- 35 data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and
- 36 real-world data. We also estimate the potential number of lives saved if CCP had been deployed
- 37 for 100% of hospitalized patients or used in 15% to 75% of outpatients. Depending on the
- assumptions modeled in stratified analyses, CCP was estimated to have saved between 16,476
- and 66,296 lives. The CCP ideal use might have saved as many as 234.869 lives while
- 40 preventing 1,136,133 hospitalizations. CCP deployment was a successful strategy for
- ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important
- 42 implications for convalescent plasma used in future infectious disease emergencies.

43 Significance statement

- 44 When the COVID-19 pandemic struck in 2020, the population lacked immunity, no validated
- 45 therapies were available, and mortality was high. COVID-19 convalescent plasma (CCP) was
- 46 authorized in the United States for treatment of hospitalized patients based on historical
- 47 evidence of convalescent plasma (CP) efficacy and findings from a nationwide registry
- 48 suggesting that it reduced mortality. However, this decision was controversial because it was not
- 49 based on evidence from randomized controlled clinical trials. In this study, we leveraged CCP
- 50 use and mortality data combined with CCP efficacy data to show that CCP reduced mortality
- and saved tens of thousands of lives the first year of the pandemic. This provides a powerful
- 52 basis to consider CP deployment in future infectious disease emergencies.
- 53
- 54

56 Introduction

In the spring of 2020, the United States of America (USA) faced a rapidly worsening coronavirus 57 disease 2019 (COVID-19) pandemic caused by a novel infectious agent, SARS-CoV-2. In the 58 59 absence of specific therapies for COVID-19, the USA Food and Drug Administration made COVID-19 convalescent plasma (CCP) available in 2020, first under compassionate use in late 60 61 March, then under an Expanded Access Program (EAP) and registry in early April, and finally 62 under Emergency Use Authorization (EUA) in late August (1). CCP was gualified initially based on the donors having had a previously positive SARS-CoV-2 nucleic acid test, not on specific 63 64 antibody levels. The EAP registry enrolled approximately 105,000 patients by late August 2020 65 (1) and produced early evidence of safety (2, 3) and efficacy (4, 5). By the Fall of 2020 as many as 40% of hospitalized patients were being treated with CCP (6). However, disappointing results 66 67 from several randomized controlled trials (RCTs) assessing CCP efficacy in hospitalized patients 68 in India (7), Argentina (8), the United Kingdom (9), and Italy (10), combined with the availability of small molecule antivirals in the form of remdesivir, led to a substantial decline in use by early 69 2021; we previously estimated this decline was associated with as many as 30,000 excess 70 71 deaths by mid-2021 (6).

72 In retrospect, early RCTs examining CCP efficacy in hospitalized patients were unlikely to show

benefit because of design flaws that included use of plasma with inadequate specific antibody

concentrations, inexact endpoints, late CCP administration (*e.g.* use during the inflammatory

phase rather than the viral phase of COVID-19), and/or insufficient power (11, 12). The early

76 phase of the pandemic in the USA also precluded a number of factors vital for conduct of

successful RCTs including: (i) training of sites and site initiation visits; (ii) precise pre-

deployment of CCP; (iii) a moving pandemic that affected different geographic regions

differently; (iv) impaired access to research staff due to work lockdowns; and (v) the lack of a
 national network to conduct pandemic related research smoothly and seamlessly. Although not

81 known at the time. later retrospective analysis of EAP data showed that distance between CCP

82 collection and use also reduced efficacy (13), adding another variable that could have

influenced the outcome of some RCTs. Subsequent trials of CCP using units with high levels of

84 spike-protein specific IgG (high titer CCP) early in disease eventually established its efficacy

85 (14, 15). However, by the time this information was available, rapid acquisition of antibody

86 immunity from natural infection and vaccination in the general population, combined with

87 widespread availability of small molecule antiviral agents and monoclonal antibodies (mAbs),

88 lowered the demand for this passive antibody therapy. Nonetheless, CCP has retained a role in

89 the COVID-19 therapeutic armamentarium in immunosuppressed patients, in whom, even in the

90 first year of the pandemic there was evidence for efficacy (16). With the loss of mAb efficacy
91 due to continued SARS-CoV-2 evolution (17), CCP is again the only available antibody-based

91 due to continued SARS-Cov-2 evolution (17), CCP is again the only available antibo

92 with activity against SARS-CoV-2 (18).

93 Four lines of evidence show that CCP reduces COVID-19 inpatient mortality when used early in

disease: 1) registry data from the USA (5), Argentina (19) and Italy (20); 2) real world data from

use in the USA (21); 3) a meta-analysis of over 30 RCTs (22); and 4) epidemiologic data

showing a strong negative correlation between CCP use and mortality, with a reciprocal

97 relationship between weekly use and the national death rate (6). From the available

98 epidemiological data, it was estimated that had the USA not deployed CCP in 2020,

approximately 96,000 additional deaths would have occurred during the first year of the

pandemic (6). In the present analysis we revisit the question of how CCP use affected overall

4

101 USA mortality by combining CCP usage data with mortality statistics and efficacy measures

102 from RCTs and real-world data.

103 Results

104 Actual lives saved in hospitalized patients. Although most patients hospitalized with COVID-19

- 105 had progressed past the interval of optimal CCP efficacy, virtually all CCP used in the USA
- 106 involved hospitalized patients, reflecting the initial EUA restriction to inpatient use. Only in
- 107 December 2021, after an outpatient RCT revealed efficacy (14), did the FDA authorize
- 108 outpatient use, and then only in immunosuppressed patients. Using the 647,795 CCP units
- 109 dispensed from July 2020 to March 2021 as a measure of the number of patients treated and
- 110 applying the mortality reduction measures from various published studies (21, 22), we
- 111 calculated that CCP deployment in the United States saved between 16,585 to 67,706 lives in
- 112 this period of the pandemic (Table 1). Importantly, even with the conservative estimate of 113
- mortality reduction of 13%, a significant number of lives were saved (95% Credible Interval (CI): 4,356 to 36,032) (Table 1). The range in crude estimates reflects the different assumptions and
- 114 115
- methods used in calculating the estimate. Although this range is large, all models converge
- 116 upon the conclusion that CCP saved lives, as indicated by the credible intervals.
- 117 Potential lives saved with optimal CCP deployment. We next estimated the hypothetical efficacy
- of CCP treatment if infrastructure had already been in place to collect, manufacture, and 118
- 119 distribute high titer CCP to 100% of hospitalized patients within 3 days of admission.
- 120 Depending on the COVID-19 mortality estimate Models 3 and 4 yield from 37,467 to 149,318
- 121 and 53,943 to 215,614 lives saved, respectively, each of which would be statistically significant
- 122 based on the credible intervals (Table 1).
- 123 Using data from five outpatient RCTs (15), it is possible to estimate the effect of CCP on
- 124 mortality had this therapy been authorized for outpatient use in the early days of the pandemic.
- However, outpatient deployment would have required specialized infrastructure that was not 125
- immediately available at the time. Furthermore, some physicians were concerned about 126
- 127 potential side effects such as antibody-dependent enhancement and antibody-triggered cytokine
- 128 storms (23). Early outpatient use of CCP would have required a monitored environment similar
- 129 in some ways to the inpatient environment (24). But by May 2020 (2), we had learned that CCP
- 130 is a safe inpatient therapy (25), and by Fall 2020 it had been used successfully in an outpatient
- 131 RCT (26) without safety concerns (27).
- 132 Although the logistics of outpatient CCP use are more complicated than in-hospital use (24),
- 133 successful deployment of outpatient mAb therapy and the availability of outpatient RCT data
- 134 (14, 28) established the feasibility of this option in the USA. Efficacy of outpatient use of CCP
- 135 was estimated in three ways: a 30% reduction in hospitalization based on a meta-analysis of
- 136 five trials (29): a 54% reduction based on findings of the largest RCT (14); and an 80%
- 137 reduction based on findings from the subset treated within 5 days in the largest RCT (30).
- 138 However, the more complex logistics of outpatient CCP use make it unlikely that everyone at
- 139 risk for progression would have received this therapy as only 15% of eligible patients received
- 140 mAb outpatient therapy (31). Had a similar percentage of high-risk individuals been treated with
- 141 CCP in the first year of the pandemic, we estimate that between 85,268 and 227,377
- 142 hospitalizations could have been avoided, depending on the efficacy estimate. Using the 21%
- 143 overall mortality rate for hospitalized patients at that time, this would have further prevented

about 17,693 to 46,974 deaths, depending on the efficacy estimate, since most deaths from
 COVID-19 occurred in hospitals (Figure 1, Table 1).

146 Reduction in hospitalizations would have also reduced stress on the health care system, which 147 itself was associated with 2,000-80,000 additional deaths from causes other than COVID-19 in 148 the first year of the pandemic (32). These estimates suggest that the secondary effects in 149 reducing hospital stress might have saved additional lives, increasing our estimates of lives 150 saved according to Model 1 (Table 1) from a minimum of 18,476 (16,476 + 2000) to a maximum 151 of 146,296 (66,296 + 80,000). Had public health and medical authorities been able to provide 152 CCP to 75% of high-risk patients (Model 4), these numbers would have risen to between 55,943 153 (53,943 + 2000) to 395,6147 (215,614 + 80,000). With 407,100 USA deaths during the first year 154 of the pandemic, such a deployment would have reduced mortality by 13-72% and substantially 155 mitigated the impact of the pandemic in the USA. Given an average hospitalization cost of 156 \$41,000 per patient (33) and an average cost of \$750 per unit of CCP, we estimate outpatient 157 deployment with treatment of only 15% of eligible patients, with a 54% reduction in progression 158 to hospitalization (14), would have saved the USA approximately \$6 billion. If given to 75% of

- 159 eligible patients, savings would approach \$31 billion.
- 160 Figure 1 shows estimated lives saved with different mortality reduction assumptions and

161 potential lives saved had universal CCP use been instituted for hospitalized patients. Because it

162 is uncertain which mortality reduction value is most tenable, we opted to present all the

163 estimates in Table 1 and the most conservatives estimates only in Figure 1. Despite these

164 variations, all estimates show that thousands of lives were saved by CCP deployment.

165 Safety of CCP. Intrinsically linked to the conclusion that CCP saved lives is the assumption that 166 transfusion of CCP is safe. Numerous observational studies and RCTs have established that 167 CCP is a safe therapy (34). However, like all generally safe drugs such as penicillin that can occasionally trigger fatal reactions (35), plasma administration was associated with severe 168 169 reactions on rare occasions. The standard transfusion reactions - transfusion related acute lung 170 injury (TRALI) and transfusion associated circulatory overload (TACO) were very rare, and while 171 antibody-dependent enhancement was feared, it was not observed (2, 3). TRALI occurs after 172 transfusion in 1 of 2000 plasma components and is fatal in 5-10% of cases (36-38). Among 173 20.000 individuals who received CCP there were 36 reports of TACO, 21 reports of TRALI and 174 21 reports of severe allergic transfusion reactions, which was similar to complication rates 175 associated with infusion of fresh frozen plasma (3), of which about 2,000,000 units are 176 transfused in the USA each year primarily to provide replacement of coagulation factors (39). At 177 least one fatal reaction to CCP infusion has been described in the literature (40). When 178 considering presumptive severe reactions from CCP administration occurring in critically ill 179 patients, it is often difficult to distinguish these from worsening of the underlying illness, 180 especially in the face of concurrent pneumonia, ARDS, ongoing mechanical ventilation, 181 ventricular dysfunction, and arrhythmias. Nevertheless, in our estimates we sought to consider 182 the worst possible scenario for CCP in contributing to COVID-19 related deaths to provide the 183 most conservative estimate of lives saved. The EAP registry recorded 63 deaths among 20,000 184 individuals transfused with CCP within 4 h of plasma infusion, of which 10 were judged as possibly related to CCP. Extrapolating this mortality rate to our study, given that 647,795 units 185 186 were administered, would mean that 32 to 324 deaths from CCP would have to be subtracted 187 from the total number of lives saved.

6

- 188 <u>A model for how CCP reduced mortality in COVID-19</u>. A causal association between CCP
- 189 usage and lives saved is strengthened by an understanding of the CCP mechanism of action.
- 190 CCP administration has been shown to reduce SARS-CoV-2 viral load in macaques (41),
- hamsters (42, 43), and mice made susceptible to this coronavirus by expressing the human
- angiotensin-converting enzyme 2 (ACE2) receptor (44, 45). In hospitalized patients,
- administration of CCP with greater neutralizing antibody content was associated with greater
- 194 SARS-CoV-2 viral load reduction (46). Both animal and clinical studies thus establish CCP as
- an antiviral therapy, consistent with the accepted view that specific antibody can neutralize viral
- particles in vivo. For both CCP and mAb preparations, the active ingredient against SARS-CoV-
- 2 is a specific antibody. Consistent with the antiviral activity of both preparations, monoclonal
- antibody RCTs reported increased rates of viral clearance in the intervention arms (47),
- 199 confirming the efficacy of specific antibody as an antiviral agent.
- 200 Dose response effects are powerful tools for establishing causality in science and medicine
- 201 (48). In this regard, several studies reported dose-response effects between CCP specific
- antibody content and favorable clinical outcomes (5, 19, 29, 49-52). Greater viral load reduction
- was also observed in hospitalized patients receiving greater quantities of CCP (two units) in an
- RCT (53). Given that specific antibody is an effective antiviral, greater efficacy for CCP units
- with higher specific antibody content can be expected to mediate stronger antiviral effects, that
- should translate into favorable outcomes.
- 207 A third line of evidence for a causal association between CCP use and reduced mortality comes
- 208 from its effects on inflammatory markers, which served as surrogate markers of COVID-19
- severity. CCP administration was associated with a reduction in markers of inflammation,
- 210 including C-reactive protein (54-56) and IL-6 (54, 57-59). Since increased levels of IL-6
- 211 correlate with increased mortality and anti-IL-6 therapy reduces COVID-19 mortality (60), CCP-
- associated reductions in IL-6 could have contributed to its effect on mortality. The anti-
- 213 inflammatory effect of CCP could be a consequence of its antibody-mediated antiviral effect
- 214 where reduced viral load elicits less inflammation and/or other components (61). Most patients
- with COVID-19 die because of profuse pulmonary inflammation that impairs gas-exchange (62).
- 216 In a Belgian RCT, CCP transfused within 48 hours of mechanical ventilation reduced
- deaths(63). Consequently, CCP anti-inflammatory effects can be incorporated into a model for
- 218 mortality reduction whereby reduced CCP reduces viral load and inflammatory cytokines and 219 thus lowers the probability of disease progression to end stage pulmonary compromise (Figure
- thus lowers the probability of disease progression to end stage pulmonary compromise (FigureIn this regard, viral clearance from both small molecule antivirals and specific antibody is a
- surrogate for clinical efficacy in preventing progression of disease (47). Consistent with the
- critical role of specific antibody in host defense, the absence of antibody to SARS-CoV-2 is a
- 222 poor prognostic marker associated with increased mortality in COVID-19 (64, 65), which
- 224 provides an additional explanation how the administration of CCP reduced mortality by providing
- 225 recipients with antibody to the virus.

226 Discussion

227 Our estimates indicate that CCP deployment in the USA in 2020 saved thousands of lives. This

228 public health benefit is in alignment with the decisions to authorize its use during a national

emergency, particularly early in the pandemic when there was a great need for effective

- therapies. Furthermore, these data support the use of this therapy in future infectious disease
- outbreaks. Our results suggest that, had more CCP use been encouraged, and had its
- availability been prioritized by medical and governmental authorities, more lives would have

233 been saved. Despite receiving emergency use authorization by the FDA in August 2020, CCP 234 use was not often recommended by guideline committees for COVID management, which held 235 out for RCT data before making recommendations, but such evidence was not available early in 236 the pandemic. Had CCP been universally deployed in hospitals, as was done for supplemental 237 oxygen and corticosteroids in hypoxic individuals, we estimate that the total lives saved among 238 hospitalized patients would have increased ranging from 36,838 to 215,195 depending on the 239 model used and the assumed efficacy. Universal use would not have been possible in the early 240 days of the pandemic when CCP was scarce but by the Fall of 2020 supplies were plentiful and 241 up to 40% of hospitalized patients in the USA were receiving CCP (6). COVID-19 was 242 particularly devastating for residents of long-term care facilities (66). Mortality rates due to 243 COVID-19 in these facilities were particularly high (67) and CCP deployment may have had an 244 outsized impact upon this population.

245 In considering our estimates, we acknowledge several limitations of the analysis. The number of 246 CCP units used for the calculations provided by the BCA does not capture all the CCP used in 247 the USA, particularly in the early days of the pandemic when some CCP was sourced locally. 248 While the exact number of units used is unknown, the estimates used in this study capture the 249 great majority of CCP used in the USA. The mortality reduction estimates used to calculate the 250 lives saved varied widely and the extent to which they resembled use and efficacy in more 251 2,000 clinical settings that used CCP throughout the USA is uncertain. Of note, CCP efficacy 252 was found to vary with distance between donor collection to patient administration sites, with a 253 significant reduction in efficacy when the distance exceeded 150 miles, likely reflecting donorrecipient mismatches arising from local viral evolution (68), a phenomenon consistent with 254 255 geographic antigenic variation by SARS-CoV-2 (13). We did not model this distance effect on 256 the potential of CCP for saving lives. Had all CCP been locally sourced our estimates of lives saved would have been higher. 257

258 In a previous epidemiologic study using regression analysis of USA population data correlating 259 weekly mortality figures with CCP use, CCP deployment was estimated to have saved about 260 96,000 lives in the first year of the pandemic (6). The difference in lives saved between the 261 epidemiologic study and the modeling estimates of the present study could arise from lower 262 efficacy in hospitalized populations studied in RCTs or from trial-associated methodological 263 differences in CCP administration. For example, RCTs inevitably included enrollment and 264 randomization protocols that may have further delayed the administration of CCP, thus reducing 265 its efficacy (11). Additionally, epidemiological analyses could have overestimated the lives saved 266 if the assumptions used to correlate overall mortality with CCP usage did not account for 267 possible confounders. Finally, this previous model estimated a base mortality of 25% which is notably higher than the approximately 21% estimated in this study and the referenced literature, 268 269 and the higher the base mortality the more lives saved. Nevertheless, both the prior (6) and 270 current analyses are consistent in concluding that CCP deployment saved tens of thousands of 271 lives.

272 Despite the apparent success of CCP in lowering COVID-19 mortality in the USA, we note that 273 many aspects of its deployment were suboptimal. Early in the pandemic the ability to test 274 donated plasma for antibody content was limited and many patients received units with little or 275 no specific antibody to SARS-CoV-2 (69, 70). In a future emergency where public health 276 authorities are again confronted with a situation where it is difficult to ascertain antibody levels 277 they might consider using two plasma units from separate donors to increase the probability of

278 providing sufficient specific antibody to the recipient (71). Once antibody levels can be 279 determined, the optimal units for plasma therapy should be those in the upper 2-3 deciles of 280 geometric mean antibody levels, which after a ten-to-twenty-fold dilution are still in the protective 281 range (71). In addition, many patients in the first year of the pandemic were treated after three 282 days of hospitalization (72), when CCP administration was likely to have little or no effect on 283 outcome (5). The COVID-19 pandemic has yielded voluminous information on effective use of passive antibody therapies that reinforce the historical evidence (11), including the importance 284 285 of using them early in the course of disease (29), the efficacy immunocompromised individuals 286 (18), and the need to use units with high pathogen-specific immunoglobulin content (51).

287 In less than a quarter of this new century, humanity has confronted no fewer than seven major viral outbreaks with pandemic potential: Severe Acute Respiratory Syndrome (SARS) in 2003, 288 289 Middle Eastern Respiratory Syndrome (MERS) in 2008, Influenza H1N1 in 2009, Ebola virus 290 (2013), Zika virus in 2015, SARS-CoV-2 in 2019 and mPox in 2022. For SARS (73), MERS 291 (74), influenza H1N1 (75), Ebola (76), SARS-CoV-2 (this study) and mPox (77), convalescent plasma (CP) was either used clinically or considered. The USA experience with CCP provides a 292 293 roadmap for future deployments of convalescent plasma (CP). Our models demonstrate that 294 the use of CP at least as a stoppap measure until additional treatments are developed and 295 mobilized should be considered part of pandemic preparedness. In addition, our estimates 296 provide robust evidence that preparedness for a future pandemic includes an outpatient 297 infrastructure that can facilitate early delivery of high titer CP. As was the case with COVID-19, 298 CP is likely to be the only pathogen-specific therapy available for new infectious disease until 299 drugs, mAbs and vaccines become available. The long record of serotherapy efficacy dates to 300 its first use in the 1890's for diphtheria management (78) and includes efficacy during the 1918 301 influenza pandemic (79). The availability of CP as soon there are survivors supports CP use 302 while safety and efficacy data are obtained as was permitted by the EAP in the USA (1).

303 The careful recording of the results of CP deployment in a registry such as the EAP (1) provides 304 information on this therapy which can inform the design of RCTs if necessary. RCTs of CP 305 efficacy should not be launched until the optimal dose and timing of the intervention is 306 established. Without this information, one runs the of risk of misleading negative trials using 307 suboptimal treatment, as occurred frequently in the early CCP trials (80). The argument that CP 308 deployment inhibits the conduct of RCTs is mistaken; at least five RCTs were completed in the 309 USA while CCP was available as part of the EAP and its subsequent use under the EUA (80). 310 Our analysis provides reassurance that FDA decisions on the deployment of CCP and the 311 enormous efforts made by physicians, blood bankers, and the public in securing plasma in the 312 first year of the pandemic saved thousands of lives.

313 Methods

314 The overarching goal of the analysis was to estimate the lives saved based on the availability of 315 CCP. To achieve this objective, we developed several models based on available CCP use and 316 mortality data from 7/18/20 through 3/6/21. Each of these models was selected to test various 317 assumptions about how the public health benefit could be measured based on published studies 318 examining the efficacy and national trends in hospitalizations and CCP utilization. Crude 319 estimates of the lives saved were obtained through direct computation using the modeling 320 frameworks described below. The specified models and crude estimates were then combined 321 with Bayesian estimation to produce credible bounds to measure the precision in the estimates

(see Supplement 1 for details on the Bayesian modeling). The following sections detail how thehyperparameters and modeling frameworks were selected.

324 CCP units used and patients treated. The number of CCP units dispensed in the USA in the first 325 year of the pandemic was obtained from the Blood Centers of America Inc (BCA, West Warwick, 326 RI), based on the reported number of units shipped from all blood supplies to hospitals 327 nationwide (6). This number does not capture CCP produced by independent hospitals and 328 transfusion centers (6) as some CCP was collected and processed locally, as previously 329 described (53, 81). Nevertheless, BCA data represents approximately 90% of all units given in 330 the US. Given that the USA FDA recommendations for CCP use in 2020 were to use one unit 331 per patient, our estimates assumed that the number of units used corresponded to the number 332 of patients treated.

- 333 <u>CCP mortality reduction percentages</u>. We made two estimates of this parameter one based on 334 RCT's and propensity matched studies, and another based on real world data. From a meta-335 analysis of all controlled studies through 2022 (39 RCTs with 21,529 participants; 70 propensity
- matched cohort studies with 50,160 participants) we estimate that CCP reduced mortality by
- 13% in all hospitalized patients and by 37% in inpatients treated early with high titer units (22).
- Using real world data, CCP was estimated to reduce mortality in all hospitalized patients by 29% and by 47% when high titer units were used early in hospitalization (21). These mortality ranges
- include the most recent RCT in hospitalized patients reporting a 21% reduction in mortality (63),
- 341 published after the above meta-analysis. Justification for the assumption of early in-hospital use
- comes from Mozaffari et al (72), who reported that by Fall 2020 over 83% of a large sample of
- 343 patients in the United States treated with CCP were being treated in the first three days of
- hospitalization. Confidence intervals reported in these studies were used to generate prior
- 345 distributions in the Bayesian framework.
- 346 <u>Estimating hospitalized lives saved by deployment of CCP</u>. The weekly number of hospitalized
- individuals, weekly deaths associated with COVID-19 estimated as previously described (6),
- 348 and weekly hospital admissions were acquired from the United States Centers for Disease
- 349 Control and Prevention (CDC) COVID-19 reporting databases. The proportion of early 350 administered CCP was calculated according to Mozaffari et al (72) who provided the
- 351 percentages of individuals treated by hospital day in a database representing 20% of all USA
- 352 hospitals.
- 353 Lives saved by CCP were calculated using the four separate estimates of mortality benefit
- conferred by CCP shown above in hospitalized patients (22), i.e. 13% or 29% for any treatment
 in hospitals; 37% or 47% if treatment was early with high titer plasma (21).
- 356 Model 1. Evaluates the question: how many lives did CCP save in comparison to a situation357 where CCP was never used? In this scenario:
- Total Deaths = (Untreated Patients * Untreated Mortality%) + (Treated Patients * Treated
 Mortality%)
- 360 We estimated the untreated mortality each week by substituting that term with [Recorded
- 361 Deaths / (Admissions Treated Patients * Mortality Reduction)]. We then calculated the lives
- 362 saved as the difference between the above and (Admissions * Untreated Mortality) where the
- 363 comparison is to the absence of CCP treatment, using the four mortality reduction fractions

10

described above from trial and real-world data (*i.e.* 13%, 29%, 37% and 47%) obtained from (21, 22).

366 **Model 2**. This model for estimating actual lives saved differs from Model 1 in that we added 367 consideration of optimal use of plasma, *i.e.* in the first three days of hospitalization. For this

estimate we used the timing of CCP administration as reported by Mozzafari (72), who reported

that by December 2020, in a sample of 20% of US hospitals, 83% of patients were receiving

- 370 CCP in the first three days of hospitalization. We used the real-world efficacy data from Arnold 371 *et al.* (21) of a 47% reduction in mortality if given in the first 3 days and no efficacy if used
- 372 thereafter. We assumed that post-December 2020 usage resembled rates observed in
- 373 December as USA physicians had apparently learned the need to use it early in the course of
- 374 hospitalization and CCP was plentiful. The lives saved estimated from this model was calculated
- using the same methodology as model 1 except that the number of treated patients each week
- and the untreated mortality rate were recalculated according to estimated early plasma use.
- 377 Models 3 and 4 estimate the number of lives that would have been saved had CCP been
- administered to 100% of hospitalized patients, using the four measures of efficacy in reducing
- 379 mortality described above. Both models are similar to model 1 except for the assumption that all
- 380 hospitalized patients received CCP.
- 381 Total Deaths = (Admissions) * (Treated Mortality%)
- 382 Model 3 Total Lives Saved = Recorded Deaths (Admissions * Treated Mortality%)
- Model 4 Total Lives Saved = (Admissions * Untreated Mortality) (Admissions * Treated
 Mortality%)

385 Models 3 and 4 both compare the number of deaths that we estimate could have been saved if all hospitalized patients had been treated in the first three days but differ in the way deaths were 386 estimated. Model 3 uses a weighted estimate of 21% average mortality based on a regression 387 388 analysis of weekly death rates previously established (6). Model 4 uses the actual number of 389 deaths reported by the USA CDC, synchronizing these to the number of admissions with a two-390 week lag to allow for deaths to occur. These assumptions add different uncertainties. The 391 accuracy of Model 3 is dependent on a regression analysis estimate while in Model 4 not all 392 deaths occurred exactly two weeks after admission and the model does not account for the 393 proportion of patients who did receive CCP, since the USA CDC mortality numbers reflect all 394 who died including those treated with CCP.

395 Model 5: Estimating potential lives saved had CCP been deployed for outpatient use.

396 Given the greater efficacy of CCP when used early in the course of disease is likely that 397 outpatient use could have saved even more lives than inpatient use. A RCT of CCP outpatient 398 efficacy early in the pandemic reported a 48% relative risk reduction in progression to severe 399 illness likely to lead to hospitalization in elderly patients (28). Subsequently, a large RCT of 400 CCP outpatient use reported a 54.3% efficacy in reducing hospitalization (14). Consequently, we 401 estimated the potential lives saved by outpatient use based on outpatient CCP efficacy data obtained during the pandemic. When CCP was given in the first five days of symptoms its 402 403 efficacy in reducing progression to hospitalization rose to 79.9%, similar to monoclonal 404 antibodies (30). A more conservative figure of 30% for outpatient CCP emerges from a meta-405 analysis of five RCTs including international trials (29). We used all three estimates – 30%, 54% 406 and 80% - as shown in Table 1. Although not all patients who died of COVID-19 died in

407 hospitals, the vast majority did (82). Consequently, it is possible to estimate lives saved by

408 deployment of outpatient CCP since individuals not admitted to hospital were assumed to

409 contribute little to the overall death rate. In this estimate, the number of lives saved is seen as

410 proportional to the number of hospitalizations avoided, assuming that the mortality rate would411 otherwise be unchanged in the hospitalized proportion of patients:

412 Total lives saved = Recorded Deaths * proportion of patients treated * efficacy of CCP

Mortality Reduction		Crude Estimate	Lives Saved ¹				
		Model 1	L				
13%		16,585	16,476 (4,356 - 36,032)				
29%		39,089	38,500 (21,151 - 60,311)				
37%		51,338	50,697 (27,185 - 78,682)				
47%		67,706	66,296 (55,752 - 77,300)				
	Model 2						
47%		53,001	55,663 (43,668 - 69,267)				
		Model 3					
13%		38,492	37,467 (9,939 - 81,676)				
29%		90,302	87,180 (48,091 - 136,024)				
37%		118,285	114,485 (61,736 - 176,767)				
47%		155,450	149,318 (125,861 - 173,712)				
		Model 4					
13%		55,078	53,943 (14,295 - 117,707)				
29%		129,394	125,680 (69,242 - 196,335)				
37%		169,620	165,182 (88,921 - 255,448)				
47%		223,157	215,614 (181,612 - 251,012)				
		Model 5					
Mortality Reduction ²	Plasma Usage ³	Crude Estimate	Total Lives Saved ^₄				
30%	15%	20,755	17,693 (9,061 - 27,813)				
54%	15%	34,736	31,762 (15,884 - 47,056)				
80%	15%	49,880	46,974 (32,058 - 56,595)				
30%	75%	90,669	88,465 (45,307 - 139,066)				
54%	75%	160,589	158,810 (79,419 - 235,279)				
80%	75%	236,328	234,869 (160,292 - 282,974)				
Mortality Reduction ²	Plasma Usage ³	Crude Estimate	Total Hospitalizations Avoided ⁴				
30%	15%	85,268	85,587 (43,833 - 134,541)				
54%	15%	153,578	153,642 (76,835 - 227,623)				
80%	15%	227,377	227,227 (155,077 - 273,767)				
30%	75%	426,331	427,933 (219,165 - 672,708)				
54%	75%	767,396	768,212 (384,173 - 1,138,121)				
80%	75%	1,136,880	1,136,133 (775,382 - 1,368,842)				

414 Table 1. Estimates of lives saved from the deployment of CCP in the USA.

¹Posterior median and 95% credible bound estimated from a Bayesian model. See Supplement
1 for details.

⁴17 ²Model 5 used three percentages of efficacy in reducing mortality and hospitalizations: The 30%

418 value comes from a meta-analysis of five outpatient RCTs that evaluated the efficacy of CCP

- (15); the 54% value comes from the largest RCT of outpatient CCP completed (14); and the
 efficacy of 80% comes from use of CCP in the first five days of symptoms (30).
- ³Percentage of use of 15% was estimated from the actual use of mAbs during the pandemic,
- 422 which was given to patients at high risk for hospitalization. The 75% estimate assumes a major 423 national effort to deploy outpatient plasma.
- ⁴Lives Saved are calculated according to CDC recorded deaths with a two-week lag period as
- 425 previously described (6), while hospitalizations avoided are calculated based on hospital
- 426 admissions with no lag period. Hypothetically the number of lives saved would be 21% of
- 427 hospitalizations avoided, but observed deaths were used to reflect a real-life outcome.

14

428 References

429		
430	1.	Senefeld JW, et al. (2021) Access to and safety of COVID-19 convalescent plasma in
431		the United States Expanded Access Program: A national registry study. PLoS Med
432		18(12):e1003872.
433	2.	Joyner MJ, et al. (2020) Early safety indicators of COVID-19 convalescent plasma in
434		5000 patients. The Journal of clinical investigation 130(9):4791-4797.
435	3.	Joyner MJ, et al. (2020) Safety Update: COVID-19 Convalescent Plasma in 20,000
436		Hospitalized Patients. Mayo Clinic proceedings 95(9):1888-1897.
437	4.	Joyner MJ, et al. (2020) Evidence favouring the efficacy of convalescent plasma for
438		COVID-19 therapy. <i>medRxiv</i> :2020.2007.2029.20162917.
439	5.	Joyner MJ, et al. (2021) Convalescent Plasma Antibody Levels and the Risk of Death
440		from Covid-19. The New England journal of medicine 384(11):1015-1027.
441	6.	Casadevall A, et al. (2021) Convalescent plasma use in the USA was inversely
442		correlated with COVID-19 mortality. <i>Elife</i> 10.
443	7.	Agarwal A, et al. (2020) Convalescent plasma in the management of moderate covid-19
444		in adults in India: open label phase II multicentre randomised controlled trial (PLACID
445		Trial). <i>BMJ</i> 371:m3939.
446	8.	Simonovich VA, et al. (2021) A Randomized Trial of Convalescent Plasma in Covid-19
447		Severe Pneumonia. The New England journal of medicine 384(7):619-629.
448	9.	Anonymous (2021) Convalescent plasma in patients admitted to hospital with COVID-19
449		(RECOVERY): a randomised controlled, open-label, platform trial. Lancet
450		397(10289):2049-2059.
451	10.	Menichetti F, et al. (2021) Effect of High-Titer Convalescent Plasma on Progression to
452		Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19
453		Pneumonia: A Randomized Clinical Trial. JAMA network open 4(11):e2136246.
454	11.	Casadevall A, et al. (2023) Convalescent plasma therapy in COVID-19: Unravelling the
455		data using the principles of antibody therapy. <i>Expert review of respiratory medicine</i> :1-15.
456	12.	Focosi D, et al. (2022) COVID-19 Convalescent Plasma and Clinical Trials:
457		Understanding Conflicting Outcomes. Clin Microbiol Rev:e0020021.
458	13.	Kunze KL, et al. (2021) Mortality in individuals treated with COVID-19 convalescent
459		plasma varies with the geographic provenance of donors. Nature communications
460		12(1):4864.
461	14.	Sullivan DJ, et al. (2022) Early Outpatient Treatment for Covid-19 with Convalescent
462		Plasma. The New England journal of medicine 386(18):1700-1711.
463	15.	Levine AC, et al. (2023) COVID-19 Convalescent Plasma Outpatient Therapy to Prevent
464		Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five
465		Randomized Trials. Clinical infectious diseases : an official publication of the Infectious
466		Diseases Society of America.
467	16.	Thompson MA, et al. (2021) Association of Convalescent Plasma Therapy With Survival
468		in Patients With Hematologic Cancers and COVID-19. <i>JAMA oncology</i> 7(8):1167-1175.
469	17.	Focosi D, McConnell S, Sullivan DJ, & Casadevall A (2023) Analysis of SARS-CoV-2
470		mutations associated with resistance to therapeutic monoclonal antibodies that emerge
471		after treatment. Drug resistance updates : reviews and commentaries in antimicrobial
472		and anticancer chemotherapy 71:100991.
473	18.	Seneteld JW, et al. (2023) COVID-19 Convalescent Plasma for the Treatment of
474		Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA network
4/5	40	open 6(1):e2250647.
4/6	19.	Gonzalez SE, et al. (2022) Timing of convalescent plasma administration and 28-day
4//		mortality in COVID-19 pneumonia. Journal of investigative medicine : the official
478		publication of the American Federation for Clinical Research 70(5):1258-1264.

479	20.	De Silvestro G, et al. (2022) Outcome of SARS CoV-2 inpatients treated with
480		convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
481		European journal of internal medicine 97:42-49.
482	21.	Arnold Egloff SA, et al. (2021) Convalescent plasma associates with reduced mortality
483		and improved clinical trajectory in patients hospitalized with COVID-19. The Journal of
484		clinical investigation 131(20).
485	22.	Senefeld JW, et al. (2023) Rates Among Hospitalized Patients With COVID-19 Treated
486		With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clinic
487		Proceedings: Innovations, Quality & Outcomes 7(5):499-513.
488	23.	de Alwis R, Chen S, Gan ES, & Ooi EE (2020) Impact of immune enhancement on
489		Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
490		EBioMedicine 55:102768.
491	24.	Bloch EM, et al. (2022) How do I implement an outpatient program for the administration
492		of convalescent plasma for COVID-19? Transfusion 62(5):933-941.
493	25.	Joyner MJ, et al. (2020) Safety Update: COVID-19 Convalescent Plasma in 20,000
494		Hospitalized Patients. Mayo Clinic proceedings, (Elsevier).
495	26.	Libster R, et al. (2020) Prevention of severe COVID-19 in the elderly by early high-titer
496		plasma. <i>medRxiv</i> :2020.2011.2020.20234013.
497	27.	Huaman MA, et al. (2023) Transfusion reactions associated with COVID-19
498		convalescent plasma in outpatient clinical trials. <i>Transfusion</i> 63(9):1639-1648.
499	28.	Libster R, et al. (2021) Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in
500		Older Adults. The New England journal of medicine 384(7):610-618.
501	29.	Levine AC, et al. (2022) COVID-19 Convalescent Plasma Outpatient Therapy to Prevent
502		Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five
503		Randomized Trials. medRxiv.
504	30.	Sullivan DJ, et al. (2023) Outpatient randomized controlled trials to reduce COVID-19
505		hospitalization: Systematic review and meta-analysis. <i>J Med Virol</i> 95(12):e29310.
506	31.	McCreary EK, Escobar ZK, & Justo JA (2023) Monoclonal Antibodies for the Treatment
507		of COVID-19-Every Day You Fight Like You're Running Out of Time. JAMA network open
508		6(4):e239702.
509	32.	French G, et al. (2022) Impact of hospital strain on excess deaths during the COVID-19
510		pandemic-United States, july 2020-july 2021. American journal of transplantation : official
511		journal of the American Society of Transplantation and the American Society of
512		Transplant Surgeons 22(2):654-657.
513	33.	Ohsfeldt RL, et al. (2021) Inpatient Hospital Costs for COVID-19 Patients in the United
514		States. Adv Ther 38(11):5557-5595.
515	34.	Franchini M, et al. (2024) Safety and Efficacy of Convalescent Plasma Combined with
516		Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A
517		Systematic Review and Meta-Analysis. <i>Diseases</i> 12(3):41.
518	35.	Rosenthal A (1954) Eight fatal anaphylactic reactions to penicillin. New York state journal
519		of medicine 54(10):1485-1487.
520	36.	Popovsky MA & Moore SB (1985) Diagnostic and pathogenetic considerations in
521		transfusion-related acute lung injury. Transfusion 25(6):573-577.
522	37.	Bux J (2005) Transfusion-related acute lung injury (TRALI): a serious adverse event of
523		blood transfusion. Vox Sang 89(1):1-10.
524	38.	Webert KE & Blajchman MA (2005) Transfusion-related acute lung injury. Curr Opin
525		Hematol 12(6):480-487.
526	39.	Arya RC, Wander G, & Gupta P (2011) Blood component therapy: Which, when and how
527		much. Journal of anaesthesiology, clinical pharmacology 27(2):278-284.

528 529	40.	Amrutiya V, et al. (2021) Transfusion-related acute lung injury in a COVID-19-positive convalescent plasma recipient: a case report. The Journal of international medical
530		research 49(8):3000605211032814.
531	41.	Carroll TD, et al. (2024) Vaccine-Boosted CCP Decreases Virus Replication and
532		Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-
533		Infected Hamsters. The Journal of infectious diseases.
534	42.	Haagmans BL, et al. (2021) SARS-CoV-2 Neutralizing Human Antibodies Protect
535		Against Lower Respiratory Tract Disease in a Hamster Model. J Infect Dis 223(12):2020-
536		2028.
537	43.	Takamatsu Y, et al. (2022) Highly neutralizing COVID-19 convalescent plasmas potently
538		block SARS-CoV-2 replication and pneumonia in Syrian hamsters. <i>Journal of Virology</i>
539		96(4):e01551-01521.
540	44.	Van Rompay KKA, et al. (2022) Early post-infection treatment of SARS-CoV-2 infected
541		macaques with human convalescent plasma with high neutralizing activity had no
542		antiviral effects but moderately reduced lung inflammation. PLoS pathogens
543	45	18(4):e1009925.
544	45.	Deere JD, et al. (2021) SARS-COV-2 Infection of Rhesus Macaques Treated Early with
545	40	Human COVID-19 Convalescent Plasma. <i>Microbiology spectrum</i> 9(3):e0139721.
540	46.	Marconato M, et al. (2022) Antibodies from convalescent plasma promote SARS-Cov-2
547		clearance in individuals with and without endogenous antibody response. The Journal of
548 570	47	Clinical Investigation 132(12). Elias KM, at al. (2024) Viral clearance as a surrogate of clinical officacy for COV/ID-19
550	47.	therapies in outpatients: a systematic review and meta-analysis. The Lancet Microbe
551	48	HILLAB (1965) THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CALISATION?
552	4 0.	Proceedings of the Royal Society of Medicine 58(5):295-300
553	49	Begin P. et al. (2021) Convalescent plasma for hospitalized patients with COVID-19 ⁻ an
554		open-label, randomized controlled trial. <i>Nature medicine</i> 27(11):2012-2024.
555	50.	Maor Y. <i>et al.</i> (2020) Compassionate use of convalescent plasma for treatment of
556		moderate and severe pneumonia in COVID-19 patients and association with IgG
557		antibody levels in donated plasma. EClinicalMedicine 26:100525.
558	51.	Park HS, et al. (2024) Outpatient COVID-19 convalescent plasma recipient antibody
559	• • •	thresholds correlated to reduced hospitalizations within a randomized trial. <i>JCI insight</i> .
560	52.	Park H. et al. (2024) Association between COVID-19 convalescent plasma antibody
561		levels and COVID-19 outcomes stratified by clinical status at presentation. BMC
562		infectious diseases 24(1):639.
563	53.	Bar KJ, et al. (2021) A randomized controlled study of convalescent plasma for
564		individuals hospitalized with COVID-19 pneumonia. The Journal of clinical investigation.
565	54.	Pratedrat P, et al. (2023) Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and
566		Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma.
567		Diseases 11(3).
568	55.	Duan K, et al. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19
569		patients. Proceedings of the National Academy of Sciences of the United States of
570		America 117(17):9490-9496.
571	56.	Perotti C, et al. (2020) Mortality reduction in 46 severe Covid-19 patients treated with
572		hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica.
573	57.	Bandopadhyay P, et al. (2021) Nature and Dimensions of Systemic Hyperinflammation
574		and its Attenuation by Convalescent Plasma in Severe COVID-19. The Journal of
575		infectious diseases 224(4):565-574.
576	58.	Habtehyimer F, et al. (2024) COVID-19 convalescent plasma therapy decreases
577		inflammatory cytokines: a randomized controlled trial. Microbiology spectrum
578		12(1):e0328623.

579	59.	Acosta-Ampudia Y. et al. (2021) COVID-19 convalescent plasma composition and
580		immunological effects in severe patients. <i>Journal of autoimmunity</i> 118:102598.
581	60.	Ghosn L, et al. (2023) Interleukin-6 blocking agents for treating COVID-19: a living
582		systematic review. The Cochrane database of systematic reviews 6(6):Cd013881.
583	61.	Focosi D, et al. (2021) COVID-19 Convalescent Plasma Is More than Neutralizing
584		Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors.
585		Viruses 13(8).
586	62.	Wu M, et al. (2020) Transcriptional and proteomic insights into the host response in fatal
587		COVID-19 cases. Proceedings of the National Academy of Sciences of the United States
588		of America 117(45):28336-28343.
589	63.	Misset B, et al. (2023) Convalescent Plasma for Covid-19-Induced ARDS in
590		Mechanically Ventilated Patients. The New England journal of medicine 389(17):1590-
591		1600.
592	64.	Dispinseri S, et al. (2021) Neutralizing antibody responses to SARS-CoV-2 in
593		symptomatic COVID-19 is persistent and critical for survival. <i>Nature communications</i>
594	. -	12(1):2670.
595	65.	Martin-Vicente M, et al. (2022) Low anti-SARS-CoV-2 S antibody levels predict
596		increased mortality and dissemination of viral components in the blood of critical
597	00	COVID-19 patients. Journal of Internal medicine 291(2):232-240.
598	66.	Bagchi S, et al. (2021) Rates of COVID-19 Among Residents and Staff Members in
599		Nursing Homes - United States, May 25-November 22, 2020. MMWR. Morbidity and
600	67	Inortality weekly report 10(2):52-55.
602	67.	Lee D, Counard C, Tang A, Brister S, & Ezike N (2022) Notes from the Fleid: COVID-19-
602 602		Dwolling Adults Aged >65 Years Illinois December 2020 and January 2022 MM/M/P
604		Marchidity and mortality wookly report 71(21):803-805
605	68	Kunze KI et al. (2021) Mortality in individuals treated with $COVID_19$ convalescent
606	00.	plasma varies with the deographic provenance of donors
607		medRxiv 2021 2003 2019 21253975
608	69.	Zhang S. et al. (2023) High-Throughput Neutralization and Serology Assays Reveal
609		Correlated but Highly Variable Humoral Immune Responses in a Large Population of
610		Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
611		mBio:e0352322.
612	70.	Klein SL, et al. (2020) Sex, age, and hospitalization drive antibody responses in a
613		COVID-19 convalescent plasma donor population. The Journal of clinical investigation
614		130(11):6141-6150.
615	71.	Sullivan D & Casadevall A (2023) COVID-19 Serology Data Provide Guidance for Future
616		Deployments of Convalescent Plasma. mBio:e0042823.
617	72.	Mozaffari E, et al. (2022) Clinical Management of Hospitalized Coronavirus Disease
618		2019 Patients in the United States. Open forum infectious diseases 9(1):ofab498.
619	73.	Cheng Y, et al. (2005) Use of convalescent plasma therapy in SARS patients in Hong
620		Kong. European journal of clinical microbiology & infectious diseases : official publication
621		of the European Society of Clinical Microbiology 24(1):44-46.
622	74.	Ko JH, et al. (2018) Challenges of convalescent plasma infusion therapy in Middle East
623		respiratory coronavirus infection: a single centre experience. Antiviral therapy 23(7):617-
624	75	622.
025 626	15.	nung IF, et al. (2011) Convalescent plasma treatment reduced mortality in patients with
020 627		severe pandemic initidenza A (HINT) 2009 VIRUS INTECTION. Clinical Intectious diseases :
027 629	76	an onicial publication of the infectious Diseases Society of America 52(4):447-456.
020 620	70.	Disease in Guinea N Engl 1 Med 37/(1):33-42
020		

18

- Bloch EM, *et al.* (2022) The Potential Role of Passive Antibody-Based Therapies as
 Treatments for Monkeypox. *mBio* 13(6):e0286222.
- Roux E, Martin L, & Chaillou A (1894) Trois cents cas de diphtérie traités par le sérum
 antidiphtérique. *Ann Inst Pasteur* 8:640-661.
- 634 79. Luke TC, Kilbane EM, Jackson JL, & Hoffman SL (2006) Meta-analysis: convalescent
 635 blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Annals of*636 *internal medicine* 145(8):599-609.
- 63780.Senefeld JW, Marks P, Casadevall A, & Joyner MJ (2023) The value of observational638registry studies for the next infectious disease emergency. *mBio* 14(6):e0256523.
- 81. Salazar E, *et al.* (2020) Significantly decreased mortality in a large cohort of COVID-19
 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV2 spike protein IgG. *The American journal of pathology*.
- 642 82. Pathak EB, Garcia RB, Menard JM, & Salemi JL (2021) Out-of-Hospital COVID-19
- 643 Deaths: Consequences for Quality of Medical Care and Accuracy of Cause of Death 644 Coding. *American journal of public health* 111(S2):S101-s106.



646

Figure 1. Bayesian estimates of total lives saved with confidence intervals given various models
 of CCP usage and efficiency from July 2020 through March 2021. A. Summations of estimated
 lives saved using the most conservative parameters of each model as a function of time
 throughout the entire period. B. Estimated lives saved in models 1 through 4 with confidence
 intervals depicted by error bars. C. Estimated lives saved in model 5 with confidence intervals

652 depicted by error bars. **D.** Estimated hospitalizations avoided in model 5 with confidence

653 intervals depicted by error bars.

20



655 Figure 2. Proposed scheme for the reduction of COVID-19 mortality by CCP. In the USA CCP 656 was used almost exclusively in hospitalized patients, of whom the majority were admitted 657 because of some pulmonary compromise. Hence, the reduced mortality described here is 658 proposed to reflect the subset that were sufficiently early in the course of disease such that the administration of antibody could modify the progression of disease to result in better outcomes. 659 CCP has been shown to have antiviral activity and to be associated with reduced inflammatory 660 mediators including IL-6. According to this scheme, CCP administration led to reduced 661 662 inflammation that translated into lower mortality for a subset of treated hospitalized patients. 663 Created with BioRender.com